Drug intelligence / Profile preview

IVS-020

Development stage: Preclinical
Lead developer: Invivoscribe
Modality: Small Molecules
Administration: Oral

Overview

IVS-020 is a preclinical small molecule program in-licensed by Invivoscribe from Domainex. It is being developed as an oral immunotherapy agent intended to treat hematological malignancies, including acute myeloid leukemia. Invivoscribe plans to leverage its diagnostics expertise and global network for the drug's development and commercialization.

Beyond the preview

Go deeper on IVS-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVS-020.

Explore the full profile